Anti-EGFR/vascular endothelial growth factor receptor-based targeted therapy as well as immunotherapy involving programmed death (PD)−1/programmed death ligand (PD-L)1 blockade have shown survival benefits in advanced CRC patients with metastasis [31]. This evidence concerns the gene EGFR and colorectal carcinoma.